Antiretroviral regimens containing a single protease inhibitor increase risk of virologic failure in young HIV-infected children

Elisabetta Walters; Kirsten Reichmuth; Angela Dramowski; Ben J Marais; Mark F Cotton; Helena Rabie

doi:10.1097/INF.0b013e318279c800

Antiretroviral regimens containing a single protease inhibitor increase risk of virologic failure in young HIV-infected children

Pediatr Infect Dis J. 2013 Apr;32(4):361-3. doi: 10.1097/INF.0b013e318279c800.

Authors

Elisabetta Walters¹, Kirsten Reichmuth, Angela Dramowski, Ben J Marais, Mark F Cotton, Helena Rabie

Affiliation

¹ Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Stellenbosch University, South Africa. ewal@sun.ac.za

PMID: 23114373
DOI: 10.1097/INF.0b013e318279c800

Abstract

Rifampin-based tuberculosis treatment can cause subtherapeutic concentrations of protease inhibitors and virologic failure in children receiving antiretroviral therapy. Among 217 children on antiretroviral therapy, tuberculosis cotreatment (in 78) was associated with virologic failure. Ritonavir-based single protease inhibitor antiretroviral therapy regimen predicted virologic failure (adjusted odds ratio 3.7, 95% confidence interval 1.5-8.9, P = 0.004) on multivariate analysis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antitubercular Agents / administration & dosage*
Child
Child, Preschool
Cohort Studies
Drug Interactions*
Female
HIV Infections / complications
HIV Infections / drug therapy*
HIV Protease Inhibitors / administration & dosage*
Humans
Infant
Male
Retrospective Studies
Risk Assessment
Treatment Failure
Tuberculosis / complications
Tuberculosis / drug therapy*

Substances

Antitubercular Agents
HIV Protease Inhibitors